Compugen Ltd.

Equities

CGEN

IL0010852080

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.92 ^USD	+1.05%		+1.59%	-3.03%

Mar. 08	Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating	MT
Mar. 05	Transcript : Compugen Ltd., Q4 2023 Earnings Call, Mar 05, 2024

Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 13, 2021 at 07:03 am EDT

Compugen Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was USD 10.264 million compared to USD 7.398 million a year ago. Net loss was USD 9.905 million compared to USD 7.128 million a year ago. Basic loss per share from continuing operations was USD 0.12 compared to USD 0.1 a year ago.

Latest news about Compugen Ltd.

Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating	Mar. 08	MT
Transcript : Compugen Ltd., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
Earnings Flash (CGEN) COMPUGEN Reports Q4 Revenue $33.5M	Mar. 05	MT
Earnings Flash (CGEN) COMPUGEN Posts Q4 EPS $0.11	Mar. 05	MT
Earnings Flash (CW9) COMPUGEN Posts Q4 EPS $0.11	Mar. 05	MT
Compugen Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 05	CI
Compugen Ltd. Announces Executive Changes	Feb. 15	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Dec. 19	MT
Sector Update: Health Care	Dec. 19	MT
Looming Inflation Data Stifle US Equity Futures Pre-Bell	Dec. 19	MT
Exchange-Traded Funds, US Equities Rise Pre-Bell Tuesday as Investors Continue to Hope for Federal Reserve Rate Cuts Soon	Dec. 19	MT
Gilead Sciences, Compugen Sign Exclusive Licensing Deal for Pre-Clinical Immunotherapy Program; Compugen Shares Soar	Dec. 19	MT
Transcript : Compugen Ltd. - Special Call	Dec. 19
Top Midday Gainers	Dec. 19	MT
Top Premarket Gainers	Dec. 19	MT
Compugen Will Be Eligible to Receive $10 Million Milestone Payment Upon Dosing of First Patient in Astrazeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer	Dec. 19	CI
Gilead Sciences, Inc. and Compugen Ltd. Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program	Dec. 19	CI
Transcript : Compugen Ltd., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Compugen Gets Nasdaq Non-Compliance Notice on Minimum Bid Price Rule	Nov. 03	MT
Compugen Ltd. Announces to Present New Data At Sitc 2023 Suggesting Leading Edge of Anti-Il18 Binding Protein Antibody, Com503, in Treating Cancer	23-10-31	CI
Sector Update: Health Care Stocks Retreating Monday Afternoon	23-10-02	MT
Compugen Gets Japanese Patent for Cancer Combination Therapy	23-10-02	MT
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer	23-10-02	CI
Transcript : Compugen Ltd., Q2 2023 Earnings Call, Aug 07, 2023	23-08-07
Compugen Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI

Chart Compugen Ltd.

Duration

Period

More charts

Company Profile

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Compugen Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.9 USD

Average target price

5.333 USD

Spread / Average Target

+180.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
COMPUGEN LTD.	-3.03%	170M
IQVIA HOLDINGS INC.	+1.51%	42.59B
MODERNA, INC.	+8.57%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B

Other Biotechnology & Medical Research